Seizures clinical trials at UCLA
8 in progress, 3 open to eligible people
Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
open to eligible people ages 18-75
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
Los Angeles 5368361, California 5332921 and other locations
FIH Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy
open to eligible people ages 18-75
This clinical trial is designed to test whether a single image-guided intracerebral administration of inhibitory nerve cells, called interneurons (NRTX-1001), into subjects with drug-resistant unilateral mesial temporal lobe epilepsy (MTLE), with or without mesial temporal sclerosis (MTS), is safe (frequency of adverse events) and effective (seizure frequency). NRTX-1001 comprises human interneurons that secrete a neurotransmitter, gamma-aminobutyric acid (GABA).
Los Angeles 5368361, California 5332921 and other locations
Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy
open to eligible people ages 1 month to 18 years
The purpose of the study is to evaluate the efficacy of perampanel as measured by the 50 percent (%) responder rate during the maintenance period of the core study for seizure frequency in participants with pediatric epileptic syndrome (Cohort 1) and partial-onset seizures (POS) (Cohort 2).
Los Angeles 5368361, California 5332921 and other locations
Long-term Safety and Tolerability of BHV-7000
Sorry, accepting new patients by invitation only
A study to determine if BHV- 7000 is safe and tolerable in adults with refractory focal onset epilepsy
Los Angeles 5368361, California 5332921 and other locations
LP352 in Children and Adults With Dravet Syndrome (DS)
Sorry, not currently recruiting here
This (DEEp SEA Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DS. The study consists of 3 main phases: Screening, Titration period, and Maintenance period, followed by a Taper period and Follow-Up. Participants will be randomized to LP352 or placebo. The total duration of the study will be approximately 24 months.
Los Angeles 5368361, California 5332921 and other locations
LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)
Sorry, accepting new patients by invitation only
This (DEEp OLE Study) is a multicentre, open-label study to investigate the long-term safety, efficacy, tolerability, and pharmacokinetics (PK) of LP352 in the treatment of seizures in children and adults with DEE who completed Study LP352-301 or LP352-302. The study consists of 3 main phases: Screening, Titration period and Maintenance period, followed by a Taper period and Follow-Up. The total duration of the study will be approximately 14 months.
Los Angeles 5368361, California 5332921 and other locations
ZX008 in Subjects With CDKL5 Deficiency Disorder
Sorry, in progress, not accepting new patients
This is a multicenter, double-blind, parallel-group, placebo controlled, 2-part study to evaluate the efficacy and safety of ZX008 when used as adjunctive therapy for the treatment of uncontrolled seizures in children and adults with cyclin-dependent kinase like-5 (CDKL5) deficiency disorder (CDD).
Los Angeles 5368361, California 5332921 and other locations
Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment
Sorry, in progress, not accepting new patients
The purpose of this study is to evaluate the long-term safety in patients with TSC and refractory seizures who are currently receiving everolimus treatment in the Novartis-sponsored EXIST-3 study and who are determined to be benefiting from continued treatment as judged by the investigator at the completion of EXIST-3
Los Angeles 5368361, California 5332921 and other locations
Our lead scientists for Seizures research studies include Dawn S. Eliashiv, MD John M. Stern, MD.
Last updated: